Stockreport

ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis) [Yahoo! Finance]

ARS Pharmaceuticals, Inc.  (SPRY) 
PDF Pharma”, NASDAQ: SPRY). The agreement grants ALK exclusive global rights to the neffy ® adrenaline (epinephrine) nasal spray, with exception of the USA, Australia, New Z [Read more]